Belcesiran

N/A

Report date: 2025/11/26 13:25:30
NME

Base Information

Drug NameBelcesiran
Drug Alias NameDCR-A1ATDCR-S1459NN 6021NN6021
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionAlpha-1-antiproteinase modulatorsRNA interference
TargetsAlpha-1-antiproteinase
Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDicerna Pharmaceuticals IncAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDicerna Pharmaceuticals IncAlnylam Pharmaceuticals Inc
Active IndicationsN/A
Inactive Indicationsalpha 1-Antitrypsin Deficiency

Other Information

ATC CodeN/A
Related LinksDrugBank